Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: Target, mechanism of action, and therapeutic potential

Reviews in Medical Virology

Volumn 22, Issue 1, 2012, Pages 2-17

  Coughlin, Melissa M ^a   Prabhakar, Bellur S ^b  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; BASILIXIMAB; BELIMUMAB; BEVACIZUMAB; CANAKINUMAB; CETUXIMAB; DACLIZUMAB; DENOSUMAB; ECULIZUMAB; EPITOPE; GEMTUZUMAB OZOGAMICIN; GOLIMUMAB; HUMAN MONOCLONAL ANTIBODY; IBRITUMOMAB TIUXETAN; INFLIXIMAB; NATALIZUMAB; NEUTRALIZING ANTIBODY; OFATUMUMAB; OKT 3; OMALIZUMAB; PALIVIZUMAB; PANITUMUMAB; RANIBIZUMAB; RITUXIMAB; TOCILIZUMAB; TOSITUMOMAB I 131; TRASTUZUMAB; UNINDEXED DRUG; USTEKINUMAB;

ANTIGEN BINDING; ARTICLE; CELL IMMORTALIZATION; DRUG INDICATION; DRUG MECHANISM; DRUG TARGETING; HUMAN; IMMUNIZATION; IMMUNOTHERAPY; MOLECULAR CLONING; NONHUMAN; PROTEIN DOMAIN; SARS CORONAVIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; TRANSGENIC MOUSE; VIRUS MUTANT; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIVIRAL AGENTS; EPITOPES; HUMANS; IMMUNOTHERAPY; MEMBRANE GLYCOPROTEINS; MICE; MICE, TRANSGENIC; PROTEIN BINDING; SARS VIRUS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRAL ENVELOPE PROTEINS;

EID: 84855678360     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.706     Document Type: Article

References (95)

1. Peiris JS, Guan Y, Yuen KY. Severe acute respiratory syndrome. Nature Medicine 2004; 10: S88-S97.
2. Rota PA, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 2003; 300: 1394-1399. DOI: 10.1126/science.108952.
3. Song HD, et al. Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. Proceedings of the National Academy of Sciences of the United States of America 2005; 102: 2430-2435.
4. Molecular evolution of the SARS coronavirus during the course of the SARS epidemic in China. Science 2004; 303: 1666-1669. DOI: 10.1126/science.1092002.
5. Lang ZW, et al. A clinicopathological study of three cases of severe acute respiratory syndrome (SARS). Pathology 2003; 35: 526-531. DOI: 10.1080/00313020310001619118.
6. Nicholls J, et al. SARS: clinical virology and pathogenesis. Respirology 2003; 8 Suppl: S6-S8.
7. Nicholls JM, et al. Lung pathology of fatal severe acute respiratory syndrome. Lancet 2003; 361: 1773-1778.
8. To KF, et al. Tissue and cellular tropism of the coronavirus associated with severe acute respiratory syndrome: an in-situ hybridization study of fatal cases. The Journal of Pathology 2004; 202: 157-163. DOI: 10.1002/path.1510.
9. Nicholls JM, et al. Time course and cellular localization of SARS-CoV nucleoprotein and RNA in lungs from fatal cases of SARS. PLoS Medicine 2006; 3: e27.
10. Shieh WJ, et al. Immunohistochemical, in situ hybridization, and ultrastructural localization of SARS-associated coronavirus in lung of a fatal case of severe acute respiratory syndrome in Taiwan. Human Pathology 2005; 36: 303-309.
11. Ye J, et al. Molecular pathology in the lungs of severe acute respiratory syndrome patients. American Journal of Pathology 2007; 170: 538-545.
12. Li L, et al. SARS-coronavirus replicates in mononuclear cells of peripheral blood (PBMCs) from SARS patients. Journal of Clinical Virology 2003; 28: 239-44.
13. Liu CL, et al. Clinical and laboratory features of severe acute respiratory syndrome vis-a-vis onset of fever. Chest 2004; 126: 509-517. DOI: 10.1378/chest.126.2.509.
14. Knudsen TB, et al. Severe acute respiratory syndrome--a new coronavirus from the Chinese dragon's lair. Scandinavian Journal of Immunology 2003; 58: 277-284.
15. Ding Y, et al. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. The Journal of Pathology 2004; 203: 622-630. DOI: 10.1002/path.1560.
16. Yip CW, et al. Phylogenetic perspectives on the epidemiology and origins of SARS and SARS-like coronaviruses. Infection, Genetics and Evolution 2009; 9: 1185-1196.
17. Graham RL, Baric RS. Recombination, reservoirs, and the modular spike: mechanisms of coronavirus cross-species transmission. Journal of Virology 2010; 84: 3134-3146.
18. Enserink M. Infectious diseases - Clues to the animal origins of SARS. Science 2003; 300: 1351-1351.
19. Lau SK, et al. Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats. Proceedings of the National Academy of Sciences of the United States of America 2005; 102: 14040-14045.
20. Li W, et al. Bats are natural reservoirs of SARS-like coronaviruses. Science 2005; 310: 676-679.
21. Wang LF, et al. Review of bats and SARS. Emerging Infectious Diseases 2006; 12: 1834-1840.
22. Peiris JS, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003; 361: 1767-1772.
23. Hofmann H, et al. S protein of severe acute respiratory syndrome-associated coronavirus mediates entry into hepatoma cell lines and is targeted by neutralizing antibodies in infected patients. Journal of Virology 2004; 78: 6134-6142. DOI: 10.1128/JVI.78.12.6134-6142.2004.
24. Subbarao K, et al. Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice. Journal of Virology 2004; 78: 3572-3577.
25. Yeung KS, Yamanaka GA, Meanwell NA. Severe acute respiratory syndrome coronavirus entry into host cells: opportunities for therapeutic intervention. Medicinal Research Reviews 2006; 26: 414-433. DOI: 10.1002/med.20055.
26. Marra MA, et al. The genome sequence of the SARS-associated coronavirus. Science 2003; 300: 1399-1404. DOI: 10.1126/science.1085953.
27. Li F, et al. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 2005; 309: 1864-1868.
28. Li W, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 2003; 426: 450-454. DOI: 10.1038/nature02145.
29. Wong SK et al. A 193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. Journal of Biological Chemistry 2004; 279: 3197-3201. DOI: 10.1074/jbc.C300520200.
30. Chakraborti S, et al. The SARS coronavirus S glycoprotein receptor binding domain: fine mapping and functional characterization. Virology Journal 2005; 2: 73.
31. Yi CE, et al. Single amino acid substitutions in the severe acute respiratory syndrome coronavirus spike glycoprotein determine viral entry and immunogenicity of a major neutralizing domain. Journal of Virology 2005; 79: 11638-11646.
32. Holmes KV. Structural biology. Adaptation of SARS coronavirus to humans. Science 2005; 309: 1822-1823.
33. Bosch BJ, Bartelink W, Rottier PJ. Cathepsin L functionally cleaves the severe acute respiratory syndrome coronavirus class I fusion protein upstream of rather than adjacent to the fusion peptide. Journal of Virology 2008; 82: 8887-8890.
34. Ingallinella P, et al. Structural characterization of the fusion-active complex of severe acute respiratory syndrome (SARS) coronavirus. Proceedings of the National Academy of Sciences of the United States of America 2004; 101: 8709-8714. DOI: 10.1073/pnas.0402753101.
35. Tripet B, et al. Structural characterization of the SARS-coronavirus spike S fusion protein core. Journal of Biological Chemistry 2004; 279: 20836-20849. DOI: 10.1074/jbc.M400759200.
36. Huang IC, et al. SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells. Journal of Biological Chemistry 2006; 281: 3198-3203.
37. Bartlam M, Yang H, Rao Z. Structural insights into SARS coronavirus proteins. Current Opinion in Structural Biology 2005; 15: 664-672.
38. Sainz B Jr., et al. Identification and characterization of the putative fusion peptide of the severe acute respiratory syndrome-associated coronavirus spike protein. Journal of Virology 2005; 79: 7195-7206.
39. Jeffers SA, et al. CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. Proceedings of the National Academy of Sciences of the United States of America 2004; 101: 15748-15753.
40. Han DP, Lohani M, Cho MW. Specific asparagine-linked glycosylation sites are critical for DC-SIGN- and L-SIGN-mediated severe acute respiratory syndrome coronavirus entry. Journal of Virology 2007; 81: 12029-12039.
41. Shih YP, et al. Identifying epitopes responsible for neutralizing antibody and DC-SIGN binding on the spike glycoprotein of the severe acute respiratory syndrome coronavirus. Journal of Virology 2006; 80: 10315-10324.
42. Yang ZY, et al. pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. Journal of Virology 2004; 78: 5642-5650. DOI: 10.1128/JVI.78.11.5642-5650.2004.
43. Bisht H, et al. Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proceedings of the National Academy of Sciences of the United States of America 2004; 101: 6641-6646. DOI: 10.1073/pnas.0401939101.
44. Glass WG, et al. Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. Journal of Immunology 2004; 173: 4030-4039.
45. Greenough TC, et al. Pneumonitis and multi-organ system disease in common marmosets (Callithrix jacchus) infected with the severe acute respiratory syndrome-associated coronavirus. American Journal of Pathology 2005; 167: 455-463.
46. He Y, et al. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. Journal of Immunology 2005; 174: 4908-4915.
47. He Y, et al. Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochemical and Biophysical Research Communications 2004; 324: 773-781.
48. He Y, et al. Identification of a critical neutralization determinant of severe acute \respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines. Virology 2005; 334: 74-82.
49. Keng CT, et al. Amino acids 1055 to 1192 in the S2 region of severe acute respiratory syndrome coronavirus S protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents. Journal of Virology 2005; 79: 3289-3296.
50. Li T, et al. Long-term persistence of robust antibody and cytotoxic T cell responses in recovered patients infected with SARS coronavirus. PloS One 2006; 1: e24. DOI: 10.1371/journal.pone.0000024.
51. Xu X, Gao X. Immunological responses against SARS-coronavirus infection in humans. Cellular & Molecular Immunology 2004; 1: 119-122.
52. Zhong X, et al. B-cell responses in patients who have recovered from severe acute respiratory syndrome target a dominant site in the S2 domain of the surface spike glycoprotein. Journal of Virology 2005; 79: 3401-3408.
53. Du L, et al. The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nature Reviews Microbiology 2009; 7: 226-236.
54. Yang ZY, et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 2004; 428: 561-564. DOI: 10.1038/nature02463.
55. Janeway CA, Travers P, Walport M, Shlomchik M (eds). Immunobiology. 5th edn, Garland Publishing: New York, 2001.
56. Burton DR. Antibodies, viruses and vaccines. Nature Reviews Immunology 2002; 2: 706-713. DOI: 10.1038/nri891.
57. Marasco WA, Sui J. The growth and potential of human antiviral monoclonal antibody therapeutics. Nature Biotechnology 2007; 25: 1421-1434.
58. Reading SA, Dimmock NJ. Neutralization of animal virus infectivity by antibody. Archives of Virology 2007; 152: 1047-1059. DOI: 10.1007/s00705-006-0923-8.
59. Risco C, et al. Membrane protein molecules of transmissible gastroenteritis coronavirus also expose the carboxy-terminal region on the external surface of the virion. Journal of Virology 1995; 69: 5269-5277.
60. Marshall E, Enserink M. Medicine: caution urged on SARS vaccines. Science 2004; 303: 944-946. DOI: 10.1126/science.303.5660.944.
61. Olsen CW, et al. Monoclonal antibodies to the spike protein of feline infectious peritonitis virus mediate antibody-dependent enhancement of infection of feline macrophages. Journal of Virology 1992; 66: 956-965.
62. Berry JD. Rational monoclonal antibody development to emerging pathogens, biothreat agents and agents of foreign animal disease: the antigen scale. Veterinary Journal 2005; 170: 193-211.
63. Scot CT. Mice with a human touch. Nature Biotechnology 2007; 25: 1075-1077.
64. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nature Reviews. Drug Discovery 2010; 9: 767-774.
65. Drugs @ FDA. [21 March 2011].
66. Coughlin M, et al. Generation and characterization of human monoclonal neutralizing antibodies with distinct binding and sequence features against SARS coronavirus using XenoMouse. Virology 2007; 361: 93-102.
67. Greenough TC, et al. Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. Journal of Infectious Diseases 2005; 191: 507-514.
68. Sui J, et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proceedings of the National Academy of Sciences of the United States of America 2004; 101: 2536-2541.
69. Traggiai E, et al. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nature Medicine 2004; 10: 871-875. DOI: 10.1038/nm1080.
70. Gallo ML, et al. The human immunoglobulin loci introduced into mice: V (D) and J gene segment usage similar to that of adult humans. European Journal of Immunology 2000; 30: 534-540. DOI: 10.1002/(SICI)1521-4141(200002)30:02<534::AID-IMMU534>3.0.CO;2-C.
71. Lonberg N. Human antibodies from transgenic animals. Nature Biotechnology 2005; 23: 1117-1125.
72. Berry JD, et al. Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus. Journal of Virological Methods 2004; 120: 87-96. DOI: 10.1016/j.jviromet.2004.04.009.
73. Buchholz UJ, et al. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proceedings of the National Academy of Sciences of the United States of America 2004; 101: 9804-9809. DOI: 10.1073/pnas.0403492101.
74. Coughlin MM, Babcook J, Prabhakar BS. Human monoclonal antibodies to SARS-coronavirus inhibit infection by different mechanisms. Virology 2009; 394: 39-46.
75. Duan J, et al. A human SARS-CoV neutralizing antibody against epitope on S2 protein. Biochemical and Biophysical Research Communications 2005; 333: 186-193.
76. Zhang H, et al. Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies. Journal of Virology 2004; 78: 6938-6945. DOI: 10.1128/JVI.78.13.6938-6945.2004.
77. Roberts A, et al. Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters. Journal of Virology 2005; 79: 503-511.
78. van den Brink EN, et al. Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus. Journal of Virology 2005; 79: 1635-1644.
79. Sui J, et al. Broadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathway. PLoS Pathogens 2008; 4: e1000197. DOI: 10.1371/journal.ppat.1000197.
80. ter Meulen J, et al. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. Lancet 2004; 363: 2139-2141. DOI: 10.1016/S0140-6736(04)16506-9.
81. Rockx B, et al. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge. Journal of Virology 2008; 82: 3220-3235.
82. ter Meulen J, et al. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Medicine 2006; 3: e237.
83. Xiao X, et al. Oligomerization of the SARS-CoV S glycoprotein: dimerization of the N-terminus and trimerization of the ectodomain. Biochemical and Biophysical Research Communications 2004; 322: 93-99. DOI: 10.1016/j.bbrc.2004.07.084.
84. Zhou P, et al. Immunogenicity difference between the SARS coronavirus and the bat SARS-like coronavirus spike (S) proteins. Biochemical and Biophysical Research Communications 2009; 387: 326-329.
85. Yang ZY, et al. Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proceedings of the National Academy of Sciences of the United States of America 2005; 102: 797-801. DOI: 0409065102.
86. Rockx B, et al. Escape from human monoclonal antibody neutralization affects in vitro and in vivo fitness of severe acute respiratory syndrome coronavirus. Journal of Infectious Diseases 2010; 201: 946-955. DOI: 10.1086/651022.
87. Lai MM. SARS virus: the beginning of the unraveling of a new coronavirus. Journal of Biomedical Science 2003; 10: 664-675. DOI: 10.1159/000074077.
88. Weingartl H, et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. Journal of Virology 2004; 78: 12672-12676.
89. Lin YS, et al. Antibody to severe acute respiratory syndrome (SARS)-associated coronavirus spike protein domain 2 cross-reacts with lung epithelial cells and causes cytotoxicity. Clinical and Experimental Immunology 2005; 141: 500-508.
90. Yang YH, et al. Autoantibodies against human epithelial cells and endothelial cells after severe acute respiratory syndrome (SARS)-associated coronavirus infection. Journal of Medical Virology 2005; 77: 1-7. DOI: 10.1002/jmv.20407.
91. Piedimonte G, et al. A humanized monoclonal antibody against respiratory syncytial virus (palivizumab) inhibits RSV-induced neurogenic-mediated inflammation in rat airways. Pediatric Research 2000; 47: 351-356.
92. Cheng Y, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. European Journal of Clinical Microbiology and Infectious Diseases 2005; 24: 44-46. DOI: 10.1007/s10096-004-1271-9.
93. Zhang L, et al. Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals. Journal of Medical Virology 2006; 78: 1-8. DOI: 10.1002/jmv.20499.
94. Soo YO, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clinical Microbiology and Infection 2004; 10: 676-678. DOI: 10.1111/j.1469-0691.2004.00956.x.
95. Sui J, et al. Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants. Journal of Virology 2005; 79: 5900-5906.